Your shopping cart is currently empty

SLLK, the control peptide for the TSP1 inhibitor, serves as the counterpart to LSKL.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | SLLK, the control peptide for the TSP1 inhibitor, serves as the counterpart to LSKL. |
| In vivo | On day 42, the plasma TGF-β1 level in mice administered with LSKL is considerably lower (0.10±0.01 pg/mL) than in those treated with the SLLK control peptide (0.20±0.02 pg/mL; P=0.0001). The mRNA levels are evaluated in the suprarenal aortic lysates of mice given SLLK and LSKL peptides. Additionally, Akita mice treated with 30 mg/kg of LSKL show a more than twofold increase in nephrin expression in renal lysates compared to both saline controls and SLLK-treated mice. |
| Molecular Weight | 458.60 |
| Formula | C21H42N6O5 |
| Cas No. | 2918768-29-1 |
| Smiles | [C@@H](NC([C@@H](NC([C@H](CO)N)=O)CC(C)C)=O)(C(N[C@@H](CCCCN)C(N)=O)=O)CC(C)C |
| Sequence | Ser-Leu-Leu-Lys-NH2 |
| Sequence Short | SLLK |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.